Inhibition of TGF-β1/Smad signaling reverses the dedifferentiated phenotype of thyroid cancer cells in three-dimensional culture
- 6 July 2026
- journal article
- research article
- Published by Springer Nature in Journal of Endocrinological Investigation
- Vol. 49 (10) , 2693-2707
Abstract
Purpose: Thyroid cancer is the most common malignancy of the endocrine system, with a rising global incidence. Radioactive iodine (RAI) therapy with 131I is used post-surgery to ablate residual thyroid tissue and cancer cells in differentiated thyroid cancer. However, in radioiodine-refractory cases, tumor cells often undergo dedifferentiation and develop RAI resistance, severely limiting therapeutic efficacy. Therefore, elucidating the mechanisms underlying dedifferentiation and developing strategies to restore differentiation have become a hot topic in thyroid cancer research. In this study, a three-dimensional (3D) culture model of TPC-1 thyroid cancer cells was developed using hanging drop and low-adhesion methods to mimic the dedifferentiation process in vitro. Cells cultured under 3D conditions exhibited typical dedifferentiated features, including upregulation of cancer stem cell markers, downregulation of thyroid functional proteins, and impaired radioiodine uptake. Through integrated bioinformatic analysis and immunohistochemical staining of in-house papillary thyroid carcinoma (PTC) samples, we identified transforming growth factor beta 1 (TGF-β1) as a potent inducer of thyroid cancer dedifferentiation. The TGF-β1/Smad signaling pathway was activated in PTC tissues, where it played a critical role in regulating tumor stemness and the expression of iodine-metabolizing proteins. Galunisertib, a TGF-β type I receptor kinase inhibitor, effectively blocked TGF-β1 signaling in spheroids, suppressed cancer stem cell marker expression, and enhanced radioiodine uptake through upregulation of thyroid functional proteins, establishing TGF-β1 as a therapeutic target in thyroid cancer. Collectively, the established 3D culture model serves as a robust platform for investigating dedifferentiation in thyroid cancer and provides a basis for developing novel therapies against radioiodine resistance. Plain LanguageKeywords
Funding Information
- National Natural Science Foundation of China (81972503)
- National Natural Science Foundation of China (82103656)
This publication has 55 references indexed in Scilit:
- A three-dimensional microenvironment alters protein expression and chemosensitivity of epithelial ovarian cancer cells in vitroLaboratory Investigation, 2013
- Molecular pathogenesis and mechanisms of thyroid cancerNature Reviews Cancer, 2013
- Advances in establishment and analysis of three-dimensional tumor spheroid-based functional assays for target validation and drug evaluationBMC Biology, 2012
- New Targeted Therapies for Thyroid CancerCurrent Genomics, 2011
- Role of Transforming Growth Factor Beta in the Regulation of Thyroid Function and GrowthThyroid®, 2009
- Long-Term Outcome of 444 Patients with Distant Metastases from Papillary and Follicular Thyroid Carcinoma: Benefits and Limits of Radioiodine TherapyThe Journal of Clinical Endocrinology & Metabolism, 2006
- Spheroid Preparation from Hanging Drops: Characterization of a Model of Brain Tumor InvasionJournal of Neuro-Oncology, 2004
- TGF-β-induced apoptosis in human thyrocytes is mediated by p27kip1 reduction and is overridden in neoplastic thyrocytes by NF-κB activationOncogene, 2003
- Thyroid carcinomaThe Lancet, 2003
- Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas.1998